Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle

Health-Related Quality of Life in Disease-Modifying Antirheumatic Drug–Treated Adults With Juvenile Idiopathic Arthritis Compared to Rheumatoid Arthritis and the General Population

Imane Bardan, Till Uhlig, Joe Sexton, Tore Kristian Kvien, Gunnstein Bakland, Pawel Mielnik, Yi Hu, Øyvind Molberg, Anna-Birgitte Aga and Eirik Klami Kristianslund
The Journal of Rheumatology September 2025, jrheum.2025-0384; DOI: https://doi.org/10.3899/jrheum.2025-0384
Imane Bardan
I. Bardan, MD, Department of Rheumatology, Oslo University Hospital, Rikshospitalet; Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Imane Bardan
Till Uhlig
T. Uhlig, MD, PhD, Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Till Uhlig
Joe Sexton
J. Sexton, MSc, PhD, Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Joe Sexton
Tore Kristian Kvien
T. K. Kvien, MD, PhD, Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tore Kristian Kvien
Gunnstein Bakland
G. Bakland, MD, PhD, Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gunnstein Bakland
Pawel Mielnik
P. Mielnik, MD, PhD, Section for Rheumatology, Helse Førde, Førde, Norway.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Pawel Mielnik
Yi Hu
Y. Hu, MD, PhD, Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yi Hu
Øyvind Molberg
Ø. Molberg, MD, PhD, Department of Rheumatology, Oslo University Hospital, Rikshospitalet; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Øyvind Molberg
Anna-Birgitte Aga
A.B. Aga, MD, PhD, Department of Rheumatology, Oslo University Hospital, Rikshospitalet; Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anna-Birgitte Aga
Eirik Klami Kristianslund
E.K. Kristianslund, MD, PhD, Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Eirik Klami Kristianslund
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • References
  • PDF
PreviousNext
Loading

Abstract

Objective To explore health-related quality of life (HRQOL) measured by the 36-item Short Form Health Survey (SF-36), SF-36 physical component summary (PCS), SF-36 mental component summary (MCS), and Short Form 6D (SF-6D) in adults with juvenile idiopathic arthritis (JIA) compared to patients with rheumatoid arthritis (RA) and the general population.

Methods We used 6-month follow-up data from the Norwegian Disease-Modifying Antirheumatic Drug Register (NOR-DMARD), including adult patients with JIA and RA starting or switching disease-modifying antirheumatic drug (DMARD) treatment. Age- and gender-adjusted regression analyses were used to compare outcomes among JIA, RA, and the general Norwegian population.

Results Register data were available for 232 patients with JIA and 2764 with RA at 6 months follow-up. Patients with JIA had poorer physical health compared to those with RA (adjusted difference [95% CI]: PCS -3.58 [-6.09 to -1.08]). Compared to the general population, PCS scores were lower in both JIA and RA (adjusted differences [95% CI]: JIA–general population -15.70 [-18.21 to -13.19], RA–general population -12.12 [-12.76 to -11.47]). Mental health measured by MCS was similar across the 3 groups. Average SF-6D utility levels were comparable in JIA and RA, but lower than in the general population. Similar proportions of patients with JIA and RA experienced improvements exceeding minimum clinically important difference (MCID) in SF-36 scale scores, PCS, MCS, and SF-6D after 6 months.

Conclusion Compared to patients with RA and the general population, patients with JIA had lower physical HRQOL 6 months after DMARD initiation. Mental health composite scores were similar among patients with JIA, those with RA, and the general population. Both disease groups showed similar levels of improvement with treatment.

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

The Journal of Rheumatology: 52 (11)
The Journal of Rheumatology
Vol. 52, Issue 11
1 Nov 2025
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Health-Related Quality of Life in Disease-Modifying Antirheumatic Drug–Treated Adults With Juvenile Idiopathic Arthritis Compared to Rheumatoid Arthritis and the General Population
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Health-Related Quality of Life in Disease-Modifying Antirheumatic Drug–Treated Adults With Juvenile Idiopathic Arthritis Compared to Rheumatoid Arthritis and the General Population
Imane Bardan, Till Uhlig, Joe Sexton, Tore Kristian Kvien, Gunnstein Bakland, Pawel Mielnik, Yi Hu, Øyvind Molberg, Anna-Birgitte Aga, Eirik Klami Kristianslund
The Journal of Rheumatology Sep 2025, jrheum.2025-0384; DOI: 10.3899/jrheum.2025-0384

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Health-Related Quality of Life in Disease-Modifying Antirheumatic Drug–Treated Adults With Juvenile Idiopathic Arthritis Compared to Rheumatoid Arthritis and the General Population
Imane Bardan, Till Uhlig, Joe Sexton, Tore Kristian Kvien, Gunnstein Bakland, Pawel Mielnik, Yi Hu, Øyvind Molberg, Anna-Birgitte Aga, Eirik Klami Kristianslund
The Journal of Rheumatology Sep 2025, jrheum.2025-0384; DOI: 10.3899/jrheum.2025-0384
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • References
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Evaluation of Health Disparities in Outcomes of Patients With Juvenile Idiopathic Arthritis
  • Effects of CD19 CAR T Cell Therapy on Quality of Life and Direct Healthcare Costs in Systemic Lupus Erythematosus: A Preliminary Analysis
  • Anifrolumab Therapy in Dermatomyositis: New Insights From Refractory Patients
Show more Articles

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire